Novavax (NVAX) Will Participate in World Vaccine Congress Europe
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Up)Join SI Premium – FREE
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Vivek Shinde, M.D., Vice President, Clinical Development, will deliver a presentation during the World Vaccine Congress Europe 2021. A topic of discussion will be Novavax' COVID-NanoFlu™ Combination Vaccine, which combines the company's recombinant nanoparticle protein-based COVID-19 and NanoFlu™ vaccine candidates with Matrix-M™ adjuvant in a single formulation.
Session details are as follows:
Date: | Wednesday, October 20, 2021 |
Time: | 11:30 a.m. – 12:00 p.m. Central European Time (CET) / 5:30 a.m. – 6:00 a.m. Eastern Daylight Time (EDT) |
Title: | Update on Novavax' NanoFlu vaccine and COVID-19-NanoFlu Combination Vaccine development |
Novavax Participant: | Vivek Shinde, M.D., Vice President, Clinical Development |
For more information or to register, visit the Congress website.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mainz Biomed (MYNZ) Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
- RedHill Biopharma (RDHL) Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
- Central Securities (CET) Releases Report to Stockholders
Create E-mail Alert Related Categories
Corporate News, FDARelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
